Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
- PMID: 8064230
- PMCID: PMC2191647
- DOI: 10.1084/jem.180.3.1141
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
Abstract
Psoriatic skin is characterized by microvascular hyperpermeability and angioproliferation, but the mechanisms responsible are unknown. We report here that the hyperplastic epidermis of psoriatic skin expresses strikingly increased amounts of vascular permeability factor (VPF; vascular endothelial growth factor), a selective endothelial cell mitogen that enhances microvascular permeability. Moreover, two VPF receptors, kdr and flt-1, are overexpressed by papillary dermal microvascular endothelial cells. Transforming growth factor alpha (TGF-alpha), a cytokine that is also overexpressed in psoriatic epidermis, induced VPF gene expression by cultured epidermal keratinocytes. VPF secreted by TGF-alpha-stimulated keratinocytes was bioactive, as demonstrated by its mitogenic effect on dermal microvascular endothelial cells in vitro. Together, these findings suggest that TGF-alpha regulates VPF expression in psoriasis by an autocrine mechanism, leading to vascular hyperpermeability and angiogenesis. Similar mechanisms may operate in tumors and in healing skin wounds which also commonly express both VPF and TGF-alpha.
Similar articles
-
Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.J Invest Dermatol. 1997 Mar;108(3):263-8. doi: 10.1111/1523-1747.ep12286453. J Invest Dermatol. 1997. PMID: 9036922
-
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.J Immunol. 1995 Mar 15;154(6):2801-7. J Immunol. 1995. PMID: 7876550
-
Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells.J Invest Dermatol. 1995 Jul;105(1):44-50. doi: 10.1111/1523-1747.ep12312542. J Invest Dermatol. 1995. PMID: 7615975
-
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.Am J Pathol. 1995 May;146(5):1029-39. Am J Pathol. 1995. PMID: 7538264 Free PMC article. Review.
-
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.EXS. 1997;79:233-69. doi: 10.1007/978-3-0348-9006-9_10. EXS. 1997. PMID: 9002222 Review.
Cited by
-
A water-soluble caveolin-1 peptide inhibits psoriasis-like skin inflammation by suppressing cytokine production and angiogenesis.Sci Rep. 2024 Sep 4;14(1):20553. doi: 10.1038/s41598-024-71350-1. Sci Rep. 2024. PMID: 39232048 Free PMC article.
-
[Early antiexudative response--OCT monitoring after intravitreal bevacizumab injection].Ophthalmologe. 2006 Jun;103(6):476-83. doi: 10.1007/s00347-006-1356-1. Ophthalmologe. 2006. PMID: 16763864 Review. German.
-
Vascular endothelial growth factor (VEGF) in autoimmune diseases.J Clin Immunol. 2007 May;27(3):246-56. doi: 10.1007/s10875-007-9083-1. Epub 2007 Mar 6. J Clin Immunol. 2007. PMID: 17340192 Review.
-
An important role of lymphatic vessel activation in limiting acute inflammation.Blood. 2011 Apr 28;117(17):4667-78. doi: 10.1182/blood-2010-10-316356. Epub 2011 Mar 1. Blood. 2011. PMID: 21364190 Free PMC article.
-
Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.Curr Rheumatol Rep. 2011 Aug;13(4):353-9. doi: 10.1007/s11926-011-0181-y. Curr Rheumatol Rep. 2011. PMID: 21503693 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical